Clinical practice guidelines for translating pharmacogenomic knowledge to bedside. Focus on anticancer drugs by JosÃ© A. G. AgÃºndez et al.
PERSPECTIVE ARTICLE
published: 19 August 2014
doi: 10.3389/fphar.2014.00188
Clinical practice guidelines for translating
pharmacogenomic knowledge to bedside. Focus on
anticancer drugs
José A. G. Agúndez1,2*, Gara Esguevillas 1,2 , Gemma Amo1,2 and Elena García-Martín 1,2
1 Department of Pharmacology, University of Extremadura, Cáceres, Spain
2 ISCIII Research Network of Adverse Reactions to Allergens and Drugs, Madrid, Spain
Edited by:
Luis Abel Quiñones, University of
Chile, Chile
Reviewed by:
Katherine J. Aitchison, King’s College
London, UK
Beatriz Henriques, University of
Alberta, Canada (in collaboration with
Katherine J. Aitchison)
Luis Abel Quiñones, University of
Chile, Chile
*Correspondence:
José A. G. Agúndez, Department of
Pharmacology, University of
Extremadura, Avda de la Universidad
s/n, E-10071 Cáceres, Spain
e-mail: jagundez@unex.es
The development of clinical practice recommendations or guidelines for the clinical use
of pharmacogenomics data is an essential issue for improving drug therapy, particularly
for drugs with high toxicity and/or narrow therapeutic index such as anticancer drugs.
Although pharmacogenomic-based recommendations have been formulated for over 40
anticancer drugs, the number of clinical practice guidelines available is very low. The
guidelines already published indicate that pharmacogenomic testing is useful for patient
selection, but ﬁnal dosing adjustment should be carried out on the basis of clinical or
analytical parameters rather than on pharmacogenomic information. Patient selection may
seem a modest objective, but it constitutes a crucial improvement with regard to the pre-
pharmacogenomics situation and it saves patients’ lives. However, we should not overstate
the current power of pharmacogenomics. At present the pharmacogenomics of anticancer
drugs is not sufﬁciently developed for dose adjustments based on pharmacogenomics
only, and no current guidelines recommend such adjustments without considering clinical
and/or analytical parameters. This objective, if ever attained, would require the use of
available guidelines, further implementation with clinical feedback, plus a combination of
genomics and phenomics knowledge.
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Adverse drug reactions (ADRs) constitute amajor problem in clin-
ical practice, as these reactions may result in patient risk and/or
therapeutic failure. The identiﬁcation, validation, reﬁnement, and
clinical use of biomarkers of drug response are primary objectives
in medical research. In this context, pharmacogenomic biomark-
ers have shown success as predictors of drug response and ADRs,
though several limitations and barriers hamper the widespread
clinical use of pharmacogenomic biomarkers. These factors have
been analyzed in detail elsewhere (Deverka et al., 2007; Haga and
Burke, 2008; Agundez, 2009; Agundez et al., 2009; Relling et al.,
2010; Fernandez et al., 2012; Agúndez and García-Martín, 2014;
Caudle et al.,2014;Quinones et al.,2014; Rossolatos andAitchison,
2014).
Because anticancer drugs usually show high toxicity and/or
narrow therapeutic index, the potential of pharmacogenomic
biomarkers in anticancer therapy is particularly high. Pharma-
cogenomic biomarkers can be used in anticancer therapy for
drug selection according to patient’s and/or tumor genomics,
and it is expected that – often combined with therapeutic
drug monitoring – it will constitute a powerful combination
to optimize drug dosing. Some potentially relevant pharma-
cogenomic biomarkers for anticancer drugs which already have
clinical recommendations are summarized in Table 1. In this
perspective manuscript we brieﬂy present our viewpoint on the
potential of pharmacogenomics in the clinical use of anticancer
drugs, as well as some personal insight and opinion on this
issue.
The development of clinical guidelines for implementing
pharmacogenomics knowledge in anticancer therapy is still at an
early stage. Although Table 1 shows over 40 anticancer drugs
that have practice recommendations, clinical guidelines have
been developed for a very limited number of these. These clin-
ical guidelines, which are essential to implementing the use of
pharmacogenomics (Agundez et al., 2012a,b; Crews et al., 2012;
Caudle et al., 2013, 2014; Relling et al., 2013; Quinones et al.,
2014), are being drafted for several gene/drug pairs. The Clini-
cal Pharmacogenetics Implementation Consortium (CPIC), the
Pharmacogenomics Knowledge Base (PharmGKB1, or the St.
Jude Children’s Research Hospital2 as well as other interna-
tional initiatives, are particularly active in providing guidelines
and therapeutic recommendations based on pharmacogenomic
testing.
Pharmacogenomic informationmay be used in clinical practice
at diverse levels: the most conservative pharmacogenomics views
aim to stratify patient populations (patient selection biomarkers)
into those who should or should not receive a given drug (Green
and Guyer, 2011). One step further is the use of pharmacogenomic
information as a biomarker of clinical response, with drug dose
adjustment based on pharmacogenomics tests [see for instance
(Swen et al., 2011)]. So far, most guidelines aiming to adjust dose
on the basis of pharmacogenomics information also recommend
1http://www.pharmgkb.org
2www.stjude.org/pg4kds
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Table 1 | Examples of anticancer drugs with pharmacogenomic
recommendations.
Drug Drug Bank
Accession No.
Gene/marker
Afatinib DB08916 EGFR
Arsenic trioxide DB01169 PML/RARα
Azathioprine DB00993 TPMT
Bosutinib DB06616 BRC/ABL1 Philadelphia chromosome
Brentuximab vedotin DB08870 CD30
Busulfan DB01008 Philadelphia chromosome
Capecitabine DB01101 DPYD
Cetuximab DB00002 EGFR, KRAS
Cisplatin DB00515 TPMT
Crizotinib Not available ALK
Dabrafenib DB08912 G6PD, BRAF
Dasatinib DB01254 Philadelphia chromosome
Denileukin diftitox DB00004 ILR2A
Erlotinib DB00530 EGFR
Everolimus DB01590 ERBB2, ESR1
Exemestane DB00990 ESR1
Fluorouracil DB00544 DPD
Fulvestrant DB00947 ER receptor
Geﬁtinib DB00317 EGFR, CYP2D6
Homoharringtonine DB04865 BCR/ABL1
Ibritumomab DB00078 MS4A1
Imatinib DB00619 KIT, BRC/ABL1, PDGFBR,
FIP1L1/PDGFRA
Irinotecan DB00762 UGT1A1
Lapatinib DB01259 ERBB2
Lenalidomide DB00480 5q Chromosome deletion
Letrozole DB01006 ESR1, PGR
Mercaptopurine DB01033 TPMT
Nilotinib DB04868 Philadelphia chromosome, UGT1A1
Panitumumab DB01269 EGFR, KRAS
Pazopanib DB06589 UGT1A1
Pertuzumab DB06366 ERBB2
Ponatinib DB08901 BCR/ABL1
Rasburicase DB00049 G6PD
Rituximab DB00073 MS4A1
Tamoxifen DB00675 ESR1, PGR, F2, F5
Tegafur Not available DPD
Thioguanine DB00352 TPMT
Tositumomab DB00081 MS4A1
Trametinib DB08911 BRAF
Trastuzumab DB00072 ERBB2
Tretinoin DB00755 PML/RARα
Vemurafenib DB08881 BRAF
Compiled from Agundez et al. (2012a,b), Caudle et al. (2013, 2014), and Relling
et al. (2013), (http://www.fda.gov/drugs/scienceresearch/researchareas/pharmaco
genetics/ucm083378.htm), (https://www.pharmgkb.org/page/cpicGeneDrugPairs)
and CPIC Gene-Drug Pairs (see http://www.pharmgkb.org/contributors/consortia/
cpic_gene-drug_pairs.jsp).
therapeutic drug monitoring and/or close surveillance of the clin-
ical evolution of the patients based, for instance, on analytical
biomarkers. A third step would be to substitute therapeutic
drug monitoring for pharmacogenomic information. Further
steps substituting, for instance, data on clinical evolution for
pharmacogenomic data seem unrealistic.
Our personal opinion is that for anticancer drugs pharma-
cogenomics is as yet insufﬁciently developed to go beyond the
ﬁrst step, that is, pharmacogenomics for anticancer drug ther-
apy should be limited to predicting whether individuals would
respond to a determined drug, or the odds are that a patient
will experience adverse effects with a determined drug. Accord-
ingly, CPIC guidelines on anticancer drugs are rather conservative.
These guidelines are based on the genetic status for loss of function
gene variants, making different (but somewhat overlapping) rec-
ommendations for homozygous or heterozygous carriers of defect
genes.
For azathioprine and TPMT, for example, the guidelines rec-
ommend using alternative drugs for homozygous individuals, or
decreasing starting doses, and then tritrating for drug tolerance
allowing 2–4 weeks to reach steady-state after each dose adjust-
ment in heterozygous individuals (Relling et al., 2011, 2013). For
mercaptopurine andTPMT, recommendations are to consider dif-
ferent drugs or to reduce drastically starting doses for homozygous
individuals and to adjust doses based on myelosuppression and
disease-speciﬁc guidelines, both in homozygous and heterozy-
gous individuals (Relling et al., 2011, 2013). For thioguanine and
TPMT, recommendations are to consider other drugs or to start
with drastically reduced doses and to adjust doses based on myelo-
suppression and disease-speciﬁc guidelines, both in homozygous
and heterozygous individuals (Relling et al., 2011, 2013). For
capecitabine, ﬂuorouracil, tegafur and DPYD, recommendations
are to consider alternative drugs for homozygous individuals, or to
reduce by about a 50% the starting dose and to adjust doses based
on the toxicity or the pharmacokinetics [see for instance Caudle
et al. (2013) or www.stjude.org/pg4kds].
It should be noted that these recommendations usually fall
within one of two categories: to select an alternative drug or to
reduce the starting dose by a determined percentage and then
titrate the dosage according to the patient’s response. Drug adjust-
ments therefore are not based on pharmacogenomic testing as
such. All recommended changes in drug dosage should be sup-
ported by clinical or analytical biomarkers. We do not think
that dosage recommendations should go beyond this point, that
is, at the present stage of pharmacogenomic knowledge the use
of clinical or analytical biomarkers should not be substituted
by pharmacogenomic testing. The objective of dose adjust-
ment based on pharmacogenomics tests only, if ever reached,
would require further implementation of phenotype or phar-
macokinetic inference and this would require a combination of
genomics and phenomics knowledge at a level that we do not
presently have.
When incorporating pharmacogenomics testing into routine
clinical practice, we should bear in mind that the genotype
is a surrogate biomarker of the metabolic status or the clin-
ical response of a determined individual, with a determined
drug, at a determined dose, and in a particular situation. Many
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variables inﬂuence the genotype–phenotype, gene-concentration
and gene-dose relationships. For instance, gene variations very
often do not cause relevant changes in drug plasma concentration.
Another issue is that conventional pharmacogenomic genotyping
classify alleles as functional by exclusion, that is, when no common
enzyme inactivating mutations are identiﬁed. Unless patients are
genotyped by usingwhole gene sequencing, the chances of mistyp-
ing are relatively high. Moreover, the analysis of some SNPs may
yield ambiguous genotypes making it necessary to use haplotype
reconstruction algorithms or diplotype–phenotype conversion
tables (Agundez et al., 2008). Another issue is ethnic variability
because commonly used genotyping tests may not be well suited
to all human populations (Roco et al., 2012; Moreno-Guerrero
et al., 2013).
Additional uncertainty in phenotype inference comes from the
occurrence of induction and inhibition processes that may modify
in vivo activity regardless of the genotype. Moreover, conventional
genotyping misses the inﬂuence of other gene variations. Even
taking all these issues into consideration it is clear that phenotypes
may change as a result of several factors including environmental
conditions, disease progression, concomitant drug therapy and
many other phenomic factors (Houle et al., 2010; Neuraz et al.,
2013). So far we are aware of some examples, probably the tip of
the iceberg, of elements which can modify genotype–phenotype
associations.
When developing guidelines for the clinical use of phar-
macogenomic information for the use of anticancer drugs,
these factors should be addressed in the guidelines, bearing
in mind that the combination of genotyping, drug pharma-
cokinetics, pharmacodynamics, and phenome-wide studies in
large groups of patients with different clinical situations is nec-
essary in order to gain more ground in genotype–phenotype
association. Recently the CPIC group released the develop-
ment process of guidelines designed to provide guidance to
clinicians as to how available genetic test results should be
interpreted to ultimately improve drug therapy (Caudle et al.,
2014). These guidelines are based on the assessment of a known
gene–drug relationships, the identiﬁcation of content experts
and the formation of writing committee, retrieval, summa-
rization and presentation of the evidence linking genotype to
drug variability, development of therapeutic recommendation
and assignment of strength of the recommendation, internal
and external review, and periodic review and guideline updates.
A crucial point in the development of guidelines for the clin-
ical use of pharmacogenomics information includes caveats to
the effect that non-genetic considerations are also important for
prescribing decisions. Thiopurine methyltransferase (TPMT) is
a good example of this. Whereas a strong phenotype/genotype
association exists for TPTM (Ford et al., 2009) most of the
azathioprine/mercaptopurine-induced adverse reactions and the
efﬁcacy of therapy are not explained by TPMT polymorphisms
(Palmieri et al., 2007).
Besides known and extensively discussed barriers and limi-
tations to implementing the use of pharmacogenomic testing,
related to institutional support or clinician’s awareness of the use-
fulness of pharmacogenomics testing, there an important barrier
which is attributable to the scientiﬁc community, that is, some
possible overstating of our ﬁndings or overestimating the current
power of pharmacogenomics. We believe that one of the best ser-
vices we can give to pharmacogenomic testing is to recognize its
limitations and to work to solve them. In our opinion, part of the
disenchantment experienced with pharmacogenomics in recent
years may be at least partly attributable to an overoptimistic expec-
tation of making a safe and reliable personalized dose adjustment
based on pharmacogenomics tests only. We still have a long way
to go before we can do that. In the meantime, the use of pharma-
cogenomic guidelines such as those already published by CPIC 3
and the assessment of their performance in clinical practice would
provide a highly valuable feedback that could be used to reﬁne the
whole process and eventually to gainmore groundon the inference
of drug response.
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